Drug regulator making list of dual-use APIs imported from unregistered cos

The CDSCO is strictly monitoring the import of such dual-use APIs for the last few months so as to get an idea on what kind of action should be taken

An extra dose of tax on medicines
Dual-use APIs are the ones that can be used in making special food products such as nutraceuticals apart from medicines
Press Trust of India New Delhi
2 min read Last Updated : Aug 25 2019 | 10:37 AM IST
The central drug regulator is preparing a list of active pharmaceutical ingredients (APIs), the chemicals used for making medicines that have dual-use and are being frequently imported from unregistered firms, to stop their misuse and improve quality, officials said.

"Dual-use APIs, which are being imported from unregistered companies, are comparatively cheaper and of low-quality," a senior government official said.

Dual-use APIs are the ones that can be used in making special food products such as nutraceuticals apart from medicines.

"The Central Drugs Standard Control Organisation (CDSCO), the Ministry of Health and the Department of Pharmaceuticals want to put a stop to the misuse of such dual-use APIs that are being frequently imported from unregistered sources," said another senior government official.

Once the list of such APIs are prepared, it will be submitted to the Department of Pharmacueticals, he said.

The CDSCO is strictly monitoring the import of such dual-use APIs for the last few months so as to get an idea on what kind of action should be taken, he added.

India imports almost 80 per cent of its API requirement from China.

In India, if a company has to import a dual-use API, it has to give an affidavit to the CDSCO that a particular API is being imported from a specific registered company and it will be used in making a particular medicine or medicines only.

According to the first senior official quoted above, most of such dual-use APIs are in high demand in the pharma industry as well as special food products industry. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CDSCONutraceuticalpharmaceutical firms

Next Story